Proteomics

Dataset Information

0

Identification of ubiquitination site in BCL-XL after PROTAC DT2216 treatment


ABSTRACT: The availability of a suitable lysine for PROTAC-mediated ubiquitination can also determine the degradative ability of a protein target and the selectivity of a PROTAC. PROTAC DT2216 selectively triggers ubiquitination and degradation of BCL-XL. In this study, we identify K87 is the key ubiquitinated lysine under DT2216 treatment through LC-MS/MS.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Epithelial Cell

DISEASE(S): Disease Free

SUBMITTER: Dongwen Lv  

LAB HEAD: Dongwen Lv

PROVIDER: PXD015454 | Pride | 2019-10-08

REPOSITORIES: Pride

altmetric image

Publications


B-cell lymphoma extra large (BCL-X<sub>L</sub>) is a well-validated cancer target. However, the on-target and dose-limiting thrombocytopenia limits the use of BCL-X<sub>L</sub> inhibitors, such as ABT263, as safe and effective anticancer agents. To reduce the toxicity of ABT263, we converted it into DT2216, a BCL-X<sub>L</sub> proteolysis-targeting chimera (PROTAC), that targets BCL-X<sub>L</sub> to the Von Hippel-Lindau (VHL) E3 ligase for degradation. We found that DT2216 was more potent again  ...[more]

Similar Datasets

2023-03-11 | PXD033828 | Pride
2016-06-10 | E-GEOD-74836 | biostudies-arrayexpress
2015-09-16 | E-GEOD-59518 | biostudies-arrayexpress
2020-12-01 | PXD021712 | Pride
2022-05-19 | PXD030213 | Pride
2024-01-04 | PXD043457 | Pride
2024-01-04 | PXD043454 | Pride
2010-09-01 | E-MTAB-332 | biostudies-arrayexpress
2018-11-21 | PXD010191 | Pride
2008-10-31 | E-GEOD-11004 | biostudies-arrayexpress